Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck KGaA Sees Coronavirus Impact Subsiding In Q2

As Mavenclad Sales Keep Climbing

Executive Summary

The German company is exposed to events in China across its three divisions - healthcare, life sciences and performance materials - but says that COVID-19 should only affect 2020 sales by 1%, unless a global recession happens.

You may also be interested in...



Merck KGaA Tightens Focus With Allergopharma Sale

Germany’s family-controlled big pharma, Merck KGaA, is divesting its allergens business, Allergopharma to the fast-growing Munich healthcare company, Dermapharm Holding.

Merck KGaA Keen To Remain Key Player In MS Now And In Future

The German company is predicting sales in mid-triple-digits in 2019 for Mavenclad, its multiple sclerosis drug which has just been launched in the US, and has highlighted more promising MS data for its BTK inhibitor evobrutinib.

Sir Mene Pangalos Outlines AZ's Trio Of COVID-19 Targets

The diagnostics tie-up with GSK on testing is a near-term move to help the UK get back to normality, the drug major's biopharmaceuticals R&D boss tells Scrip. AstraZeneca's main focus is to develop monoclonal antibodies to tackle 'wave two' of the coronavirus.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141785

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel